Simultaneous Therapy Approach: Systemic and Intratympanic Corticosteroid for Idiopathic Sudden Sensorineural Hearing Loss: A Clinical Study

TL;DR

This study shows that combining systemic and intratympanic corticosteroids improves hearing and symptoms in most patients with sudden hearing loss.

Contribution

The novel contribution is demonstrating the effectiveness of combined corticosteroid therapy for ISSNHL and its related symptoms.

Findings

Sixty percent of ISSNHL cases showed improvement with combined corticosteroid treatment.

Tinnitus and vertigo symptoms were significantly reduced in most patients.

Complete recovery was observed in 30% of patients after one month of treatment.

Abstract

Idiopathic Sudden sensorineural hearing loss (ISSNHL) can be treated with various methods. This study investigated the impact of combined systemic and intratympanic corticosteroid injections on hearing improvement and associated symptoms in patients with ISSNHL.Top of Form.

The study investigated the recovery process of 73 patients with ISSNHL from Khorasan Razavi registry between the years 2022 to 2024. These patients received treatment involving both systemic and intratympanic corticosteroid.

One month after treatment, the study using Modified Siegel's criteria found complete, partial, and slight improvement in 30%, 14%, and 16% of patients, respectively. During this period, 24% of cases with tinnitus were completely treated, while 51% experienced partial relief. For cases with vertigo, 67% were completely treated, and 33% had partial improvement.

Combined corticosteroid treatment is effective in approximately sixty percent of ISSNHL cases. This therapy also demonstrates success in alleviating related symptoms such as tinnitus and vertigo.

Figures